Pressure Builds On U.K. Government To Conclude Value-Based Pricing Deal With Industry
This article was originally published in The Pink Sheet Daily
An influential parliamentary committee has called on the U.K. to reveal its plans for value-based pricing by the end of March so that companies, clinicians and patients can adjust to the change, which is expected to start in 2014.
You may also be interested in...
Negotiations will start in September 2012 on a value-based pricing approach for new medicines in the U.K., and on a new PPRS scheme for currently marketed drugs, with a new suggestion: oncologics previously rejected by NICE might be reviewed again under the new VBP system.
With eighteen months until the start of a new drug pricing scheme, the slow progress and lack of detail on the U.K.'s value-based pricing (VBP) approach worries industry and suggests transitional arrangements may be necessary.
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.